Mike
Analyst
Morgan Stanley
Equibles does not estimate personal net worth.
About Mike
Mike is recorded as Analyst at Morgan Stanley. Mike has spoken on 4 earnings calls across 4 companies, most recently for Jazz Pharmaceuticals plc on November 2, 2026. Those appearances were for Jazz Pharmaceuticals plc (JAZZ), Sarepta Therapeutics, Inc. (SRPT), Biomarin Pharmaceutical Inc (BMRN) and Alnylam Pharmaceuticals, Inc. (ALNY). The companies whose calls Mike spoke on are classified in the Healthcare sector.
Mike on recent calls
“Any commentary on why the high-sodium generics aren't causing that erosion? Maybe, like, what are you learning about the market's willingness to accept high-sodium regimens, and has anything maybe changed your thinking of how you think LumeRise would perform in IH once it gets on market?”
“Maybe just with respect to the RNA data updates expected later in the second half, should we expect those more towards year end? And will you share those updates together, or do you plan to separate them out?”
“And with regard to that safety profile we're not anticipating any unexpected events there as well so fingers crossed and we'll be updating you all when that data is available thank you so much that's really helpful and then just maybe circling back onto the intro comments regarding the integration of amicus you…”
“Maybe I could ask a question just on cardiomyopathy and trends there, particularly for market share. Obviously, you've had some great share gains in the second line setting and also positive trends in the front line.”
Affiliation history
-
Morgan Stanley
Analyst
Transcript header (unverified)
Current